Skip to content
10-Q

Quarterly Report

Dyne Therapeutics, Inc. DYN

0001193125-26-215702

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q1 2026 · Mar 31, 2026 $221K
Capex Q1 2026 · Mar 31, 2025 $981K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$144.92M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$105.89M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $753.1M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $893.37M
Stockholders Equity Q1 2026 · Mar 31, 2026 $865.06M
Stockholders Equity Q1 2026 · Dec 31, 2025 $972.13M
Stockholders Equity Q1 2026 · Mar 31, 2025 $668.97M
Stockholders Equity Q1 2026 · Dec 31, 2024 $629.84M
Current Liabilities Q1 2026 · Mar 31, 2026 $51.25M
Current Liabilities Q1 2026 · Dec 31, 2025 $50.63M
Total Liabilities Q1 2026 · Mar 31, 2026 $214.9M
Total Liabilities Q1 2026 · Dec 31, 2025 $214.83M
Current Assets Q1 2026 · Mar 31, 2026 $1.02B
Current Assets Q1 2026 · Dec 31, 2025 $1.13B
Total Assets Q1 2026 · Mar 31, 2026 $1.08B
Total Assets Q1 2026 · Dec 31, 2025 $1.19B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.73
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.05
Eps Basic Q1 2026 · Mar 31, 2026 −$0.73
Eps Basic Q1 2026 · Mar 31, 2025 −$1.05
Sga Expense Q1 2026 · Mar 31, 2026 $24.39M
Sga Expense Q1 2026 · Mar 31, 2025 $15.93M
Rd Expense Q1 2026 · Mar 31, 2026 $100.89M
Rd Expense Q1 2026 · Mar 31, 2025 $106.45M
Net Income Q1 2026 · Mar 31, 2026 −$120.85M
Net Income Q1 2026 · Mar 31, 2025 −$115.36M
Operating Income Q1 2026 · Mar 31, 2026 −$125.28M
Operating Income Q1 2026 · Mar 31, 2025 −$122.37M